Parental Project and Premature Ovarian Insufficiency (ParentIOP)

October 3, 2022 updated by: Assistance Publique - Hôpitaux de Paris

One of the main repercussions of POI is infertility. When the diagnosis of POI is announced, the question of fertility is addressed and the patient is often directed towards egg donation or adoption when she has a parental project. However, there are cases of spontaneous pregnancies after diagnosis.

This study was conducted to determine the proportion of patients with POI who were able to realize a parental project after diagnosis in the long term and by what means.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The investigators propose to study patients with POI who were hospitalized in the endocrinology and reproductive medicine department of the Pitié-Salpêtrière Hospital for the etiological assessment of ovarian failure and its consequences between December 31, 1982 and January 12, 2021. The investigators will only include patients who were admitted to the day hospital because we have a complete etiological workup and a complete history for them, which allows investigators to describe the population properly. The patients must be over 18 years old at the time of the survey in order to be able to evaluate the presence of a parental project only in adult patients.

Patients for whom there is no valid contact information in the computer file (postal address or valid email address or cell phone number) or whose last consultation was more than 2 years ago will be excluded. Patients with Turner syndrome will be excluded because they may have comorbidities, particularly cardiac, that contraindicate pregnancy. Patients with POI secondary to oncological treatments (gonadotoxic chemotherapy or pelvic radiotherapy) will also be excluded because of the uncertain prognosis and the contraindications to pregnancy in case of hormone-dependent tumors.

Study Type

Observational

Enrollment (Actual)

324

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75013
        • Service d'endocrinologie et médecine de la reproduction

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Patients with POI who were hospitalized in a day hospital (HDJ) in the endocrinology and reproductive medicine department of the Pitié-Salpêtrière hospital for the etiological assessment of ovarian insufficiency and its repercussions between 31/12/1982 and 12/01/2021

Description

Inclusion Criteria:

  • Patients at least 18 years old at the time of the survey
  • Patients with a diagnosis of PIO according to the current definition: cycle disturbances of more than 4 months and FSH > 25 on 2 measurements one month apart
  • Patients having been hospitalized in day hospital (HDJ) in the endocrinology and reproductive medicine department of the Pitié-Salpêtrière hospital for the etiological assessment of ovarian insufficiency and its repercussions between December 31, 1982 and January 12, 2021
  • Valid contact information available: address, cell phone, e-mail
  • Patients who have been informed and do not object to participate in the study

Exclusion Criteria:

  • Turner syndrome
  • POI secondary to oncology treatments (chemotherapy, pelvic radiotherapy)
  • Opposition to participating in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Realisation of parental project
Time Frame: data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
Determine proportion of patient who realised a parental project after the diagnosis of POI
data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Determine how and to what extent they have carried out their parental project
Time Frame: data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
Evaluation if, after the diagnosis of POI, the parental project was realized through: spontaneous pregnancy or egg donation, simple stimulation or in vitro fertilization, embryo reception, or the adoption of a child after the diagnosis of POI
data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
determine how many children on average these patients had after the diagnosis of POI.
Time Frame: data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
Evaluation of the number of children born after the diagnosis of POI
data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
determine the delay between the diagnosis of POI and the birth of the first child after the diagnosis according to the method
Time Frame: data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
Evaluation of the time between the diagnosis of POI and the birth of the first child after diagnosis according to the method (egg donation, spontaneous pregnancy, adoption, etc.)
data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
Survey. Describe the characteristics of patients who were able to have a child after diagnosis
Time Frame: data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed

Evaluation of the characteristics of patients who were able to have a child after diagnosis:

o age at diagnosis

data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
Survey. Describe the characteristics of patients who were able to have a child after diagnosis
Time Frame: data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed

Evaluation of the characteristics of patients who were able to have a child after diagnosis:

o AMH level

data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
Survey. Describe the characteristics of patients who were able to have a child after diagnosis
Time Frame: data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed

Evaluation of the characteristics of patients who were able to have a child after diagnosis:

o FSH level

data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
Survey. Describe the characteristics of patients who were able to have a child after diagnosis
Time Frame: data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed

Evaluation of the characteristics of patients who were able to have a child after diagnosis:

o presence of follicles on ultrasound

data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
Survey. Describe the characteristics of patients who were able to have a child after diagnosis
Time Frame: data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed

Evaluation of the characteristics of patients who were able to have a child after diagnosis:

o cause of POI

data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
Survey. Describe the characteristics of patients who were able to have a child after diagnosis
Time Frame: data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed

Evaluation of the characteristics of patients who were able to have a child after diagnosis:

o number of pregnancies prior to diagnosis

data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
Survey. Describe the characteristics of patients who were able to have a child after diagnosis
Time Frame: data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed

Evaluation of the characteristics of patients who were able to have a child after diagnosis:

o number of children before diagnosis

data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
Survey. Describe the characteristics of patients who were able to have a child after diagnosis
Time Frame: data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed

Evaluation of the characteristics of patients who were able to have a child after diagnosis:

o normal puberty

data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed
Survey. Describe the characteristics of patients who were able to have a child after diagnosis
Time Frame: data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed

Evaluation of the characteristics of patients who were able to have a child after diagnosis:

o age at menarche

data from patients with a diagnosis between 31/12/1982 and 12/01/2021 and whose opposition to the study is not expressed

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Philippe Touraine, Pr, APHP

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 20, 2022

Primary Completion (Actual)

June 20, 2022

Study Completion (Actual)

June 20, 2022

Study Registration Dates

First Submitted

March 21, 2022

First Submitted That Met QC Criteria

April 4, 2022

First Posted (Actual)

April 5, 2022

Study Record Updates

Last Update Posted (Actual)

October 4, 2022

Last Update Submitted That Met QC Criteria

October 3, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infertility

Clinical Trials on Survey

3
Subscribe